An adaptive faculty development program for improving teaching skills.

The purpose of this study was to evaluate the efficacy of intraarterial low-dose recombinant tissue plasminogen activator (rt-PA) in patients with acute or subacute thrombosis of the native arterial system or in an arterial artificial or venous by-pass graft. Twenty patients with 22 cases of thrombosis received intraarterial thrombolysis during the period 1.1.1995 to 31.12.1995. Ten patients (50%) achieved complete radiological thrombolysis, and in seven patients (35%) partial thrombolysis was achieved. Half of these patients required a subsequent PTA or an operation. There were only three patients (15%) where no lysis occurred. The results seemed very satisfactory and we conclude that thrombolysis should be considered as the first-choice treatment in this category of patients. The indications may be extended to patients with critical ischaemia with the introduction of the pulse-spray technique as the time to complete lysis is considerably shorter with this technique.

Evaluation Studies as Topic↗

PubMed1997

Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method.

BACKGROUND: Consistency in prostate-specific antigen (PSA) quantitation by different PSA test manufacturers would minimize potential clinical confusion. The Ciba Corning ACS PSA2 calibration has been adjusted for alignment with a proposed international standard and clinical concordance with the Hybritech Tandem R assay. Herein we evaluate the clinical effectiveness of this recalibrated PSA test by comparing it with the IMx (Abbott Laboratories) and Tandem R (Hybritech) assays. METHODS: Archival serum was used that had been stored at -70 degrees C from men who underwent ultrasound-guided prostate needle biopsy. Assays were run according to each manufacturer's specifications in singlicate on a single thaw. RESULTS: The study included sera of 191 patients; 44 of the patients had carcinoma. There were 151 men with PSA (Tandem R) in the range of 0-10.0 ng/ml, 28 of whom had cancer. The correlation coefficients for Tandem R versus ACS, Tandem R versus IMx, and ACS versus IMx were 0.958, 0.955, 0.979 for benign patients and 0.960, 0.954, and 0.985 for those with cancer, respectively. The corresponding slopes were 1.029, 0.855, and 0.824 for men without and 1.044, 0.830, and 0.790, respectively, for those with malignancy. CONCLUSIONS: These data demonstrate substantial equivalence of the restandardized ACS assay and of the Hybritech method. Significant bias exists between these methods and the IMx assay with lower results being identified with the latter. These findings have significant implication, particularly in screening when results of an IMx assay are compared to other assays.

Evaluation Studies as Topic↗